Alto Neuroscience (ANRO) Depreciation and Depletion (2024 - 2026)
Alto Neuroscience (ANRO) posted Depreciation and Depletion of $200000.0 for Q1 2026, up 2.04% sequentially from $196000.0 in Q4 2025, and little changed YoY from $200000.0 in Q1 2025.
Alto Neuroscience (ANRO) Depreciation and Depletion (2024 - 2026) Analysis & Trends
Alto Neuroscience has reported Depreciation and Depletion for 3 years, with the latest figure at $200000.0 in Q1 2026.
- Quarterly Depreciation and Depletion changed 0.0% year-over-year to $200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $796000.0 (changed N/A YoY) and the FY2025 annual result came in at $700000.0, up 39.44% from the prior year.
- Depreciation and Depletion rose to $200000.0 in Q1 2026 per ANRO's latest filing, from $196000.0 in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $202000.0 in Q4 2024 and troughed at $196000.0 in Q4 2025.
- A 3-year average of $199666.7 and a median of $200000.0 in 2024 frame the typical range for Depreciation and Depletion.
- The widest YoY moves for Depreciation and Depletion: up 0.0% in 2025, down 2.97% in 2025.
- Over 3 years, Depreciation and Depletion stood at $202000.0 in 2024, then fell by 2.97% to $196000.0 in 2025, then climbed by 2.04% to $200000.0 in 2026.
- According to Business Quant data, Depreciation and Depletion over the past three periods registered $200000.0, $196000.0, and $200000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 38.91 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 196,000.00 |
| Dec 31, 2025 | 196,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 202,000.00 |
| Dec 31, 2024 | 202,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |